Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

被引：0
|
作者：
Ramakrishnan, Karthik
Mojebi, Ali
Ayers, Dieter
Chirovsky, Diana Romana
Borse, Rebekah
Keeping, Sam
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] PRECISIONheor, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18012
引用
收藏
页数：2
相关论文
共 50 条
  • [41] RAMUCIRUMAB IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS-CELL CARCINOMA: A PHASE 1-2 TRIAL
    Adkins, Douglas
    Ley, Jessica
    Palka, Kevin
    Jacobs, Miriam
    Liu, Jingxia
    Oppelt, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A385 - A385
  • [42] PEMBROLIZUMAB PLUS AXITINIB (P plus A) VERSUS OTHER FIRST-LINE (1L) SYSTEMIC THERAPIES FOR ADVANCED/METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCMRCC) - A NETWORK META-ANALYSIS (NMA)
    McGovern, I
    Simon, A.
    Shirali, R.
    Zhong, Y.
    Perini, R.
    Lorenzi, M.
    Adejoro, O.
    VALUE IN HEALTH, 2019, 22 : S444 - S444
  • [43] PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the US
    Hanna, Glenn J.
    Zheng, Dandan
    Gao, Wei
    Hair, Gleicy M.
    Ai, Lei
    Song, Yan
    Lerman, Nati
    Bidadi, Behzad
    Zion, Abigail
    Zou, Lin
    Tang, Yuexin
    Wang, Liya
    Merchant, Sanjay
    Black, Christopher M.
    ORAL ONCOLOGY, 2025, 161
  • [44] Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Greil, R.
    Rischin, D.
    Harrington, K. J.
    Soulieres, D.
    Tahara, M.
    de Castro, G.
    Psyrri, A.
    Baste, N.
    Neupane, P.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R., Sr.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Lin, J.
    Swaby, R. F.
    Gumuscu, B.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S660 - S661
  • [45] Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study
    Bernal, M. Oliva
    Lien, S.
    Wang, B. X.
    Yang, S. C.
    Spreafico, A.
    Jang, R.
    Elston, S.
    Jennings, S.
    Jiang, H.
    Haibe-Kains, B.
    Pugh, T.
    Ohashi, P.
    Siu, L. L.
    Hansen, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] NETWORK META- ANALYSIS (NMA) OF IMMUNOONCOLOGY (IO) TREATMENTS FOR FIRST-LINE (1L) ADVANCED OR METASTATIC MELANOMA
    Thosar, M.
    Khankhel, Z.
    McDonald, L.
    Moshyk, A.
    Ejzykowicz, F.
    Najlerahim, S.
    Farouk, A.
    Toor, K.
    Chan, K.
    VALUE IN HEALTH, 2023, 26 (12) : S25 - S25
  • [47] KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Harrington, Kevin Joseph
    Rischin, Danny
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    Castro, Gilberto
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash C.
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett Gordon Maxwell
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Zhang, Yayan
    Gumuscu, Burak
    Swaby, Ramona F.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] REAL-WORLD USE OF PEMBROLIZUMAB COMBINATION REGIMENS IN FIRST-LINE RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Black, Christopher
    Wang, Liya
    Ramakrishnan, Karthik
    Goto, Daisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A832 - A832
  • [49] Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial
    Honma, Yoshitaka
    Swiecicki, Paul L.
    Rosenberg, Ari Joseph
    Hanna, Glenn J.
    Yang Bruce, Justine
    Fujisawa, Takao
    Muro, Kei
    Kaplan, Jason B.
    Gorla, Seema Rao
    Liu, Shubin
    Meng, Changting
    Geiger, Jessica Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS148 - TPS148
  • [50] Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
    Yen, C. J.
    Klochikhin, A.
    Cohen, E.
    Vermorken, J.
    Harrington, K.
    Tahara, M.
    Ge, Y.
    Geib, J.
    Jin, F.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 101
12345